2017
Race and Sex Differences in QRS Interval and Associated Outcome Among Patients with Left Ventricular Systolic Dysfunction
Randolph TC, Broderick S, Shaw LK, Chiswell K, Mentz RJ, Kutyifa V, Velazquez EJ, Gilliam FR, Thomas KL. Race and Sex Differences in QRS Interval and Associated Outcome Among Patients with Left Ventricular Systolic Dysfunction. Journal Of The American Heart Association 2017, 6: e004381. PMID: 28320746, PMCID: PMC5523998, DOI: 10.1161/jaha.116.004381.Peer-Reviewed Original ResearchConceptsQRS durationBundle branch blockWhite patientsHeart failureBlack patientsBranch blockNon-left bundle branch block morphologyLeft ventricular systolic dysfunctionMultivariable Cox regression modelsBundle branch block morphologyLeft bundle branch blockMedian QRS durationVentricular systolic dysfunctionHeart failure patientsVentricular ejection fractionShorter QRS durationCox regression modelRisk of mortalityDuke University HospitalBlack individualsSex differencesCause mortalitySystolic dysfunctionCoronary angiographyEjection fraction
2008
Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both
Prisant LM, Thomas KL, Lewis EF, Huang Z, Francis GS, Weaver WD, Pfeffer MA, McMurray JJ, Califf RM, Velazquez EJ. Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both. Journal Of The American College Of Cardiology 2008, 51: 1865-1871. PMID: 18466801, DOI: 10.1016/j.jacc.2007.12.050.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsBiomarkersBlack or African AmericanCaptoprilFemaleHeart FailureHospitalizationHumansIncidenceMaleMiddle AgedMyocardial InfarctionRetrospective StudiesRisk FactorsSystoleTetrazolesUnited StatesValineValsartanVentricular Dysfunction, LeftWhite PeopleConceptsLeft ventricular systolic dysfunctionHeart failureAcute myocardial infarctionMyocardial infarctionBaseline characteristicsAfrican AmericansMyocardial Infarction ComplicatedAngiotensin receptor blockersCoronary risk factorsOutcomes of patientsRecurrent myocardial infarctionVentricular systolic dysfunctionSimilar clinical outcomesHF hospitalizationCardiovascular morbidityCause mortalityReceptor blockersSystolic dysfunctionVentricular dysfunctionCardiovascular mortalityWhite patientsClinical outcomesPoor outcomeVALIANT trialSubgroup analysis
2007
Racial Disparity in the Utilization of Implantable-Cardioverter Defibrillators Among Patients With Prior Myocardial Infarction and an Ejection Fraction of ≤35%
Thomas KL, Al-Khatib SM, Kelsey RC, Bush H, Brosius L, Velazquez EJ, Peterson ED, Gilliam FR. Racial Disparity in the Utilization of Implantable-Cardioverter Defibrillators Among Patients With Prior Myocardial Infarction and an Ejection Fraction of ≤35%. The American Journal Of Cardiology 2007, 100: 924-929. PMID: 17826371, DOI: 10.1016/j.amjcard.2007.04.024.Peer-Reviewed Original ResearchConceptsSudden cardiac deathLeft ventricular systolic dysfunctionVentricular systolic dysfunctionCardiac deathEjection fractionBlack patientsMyocardial infarctionSystolic dysfunctionWhite patientsPrimary preventionSignificant left ventricular systolic dysfunctionLower mean ejection fractionSudden cardiac death rateCardiac death rateMean ejection fractionPrior myocardial infarctionMultivariate logistic regressionImplantable cardioverter defibrillatorClinical characteristicsICD implantationICD useOverall mortalityProphylactic implantationPatient raceNational registry
2006
Racial Differences Among High-Risk Patients Presenting With Non–ST-Segment Elevation Acute Coronary Syndromes (Results from the SYNERGY Trial)††Disclosure: Drs. Mahaffey, Cohen, Newby, Ferguson, and Califf have received honoria for speaking from sanofi-aventis. Drs. Mahaffey, Ferguson, and Califf have acted as consultants for sanofi-aventis. Drs. Echols, Velazquez, Santos, and Gurfinkel have no financial relationships to disclose.
Echols MR, Mahaffey KW, Banerjee A, Pieper KS, Stebbins A, Lansky A, Cohen MG, Velazquez E, Santos R, Newby LK, Gurfinkel EP, Biasucci L, Ferguson JJ, Califf RM. Racial Differences Among High-Risk Patients Presenting With Non–ST-Segment Elevation Acute Coronary Syndromes (Results from the SYNERGY Trial)††Disclosure: Drs. Mahaffey, Cohen, Newby, Ferguson, and Califf have received honoria for speaking from sanofi-aventis. Drs. Mahaffey, Ferguson, and Califf have acted as consultants for sanofi-aventis. Drs. Echols, Velazquez, Santos, and Gurfinkel have no financial relationships to disclose. The American Journal Of Cardiology 2006, 99: 315-321. PMID: 17261389, DOI: 10.1016/j.amjcard.2006.08.031.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeAfrican American patientsMyocardial infarctionWhite patientsCoronary syndromeSegment elevation (NSTE) ACSST-segment elevation acute coronary syndromeElevation acute coronary syndromeBaseline clinical characteristicsFrequency of hypertensionNonfatal myocardial infarctionThirty-day deathCoronary artery bypassHigh-risk patientsOutcomes of patientsSanofi-AventisPercutaneous coronary interventionUse of angiographyNorth American patientsRacial differencesAfrican AmericansSYNERGY trialArtery bypassClinical characteristicsCoronary intervention